Bayhill Therapeutics Doses Patients With Multiple Sclerosis in a Phase II Trial and Raises an Additional $15.8 Million as an Extension to its Series B Financing.PALO ALTO, Calif. -- Bayhill Therapeutics Inc. has begun dosing patients with BHT-3009, the company's experimental drug candidate, in a Phase II company sponsored trial for multiple sclerosis. The Phase II study is a multi-center, double-blind, placebo-controlled evaluation with an MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. endpoint. In a related development, current investors indicated strong support for Bayhill's antigen-specific tolerance platform by raising an additional $15.8 million in private equity. The company has now closed its Series B round totaling $51.2 million. "In a Phase I/II trial evaluating BHT-3009 in patients with multiple sclerosis, we observed a good safety profile, and, in a small number of patients, evidence of a long-lasting antigen-specific immuno-suppression effect," said Mark W. Schwartz, PhD, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Bayhill Therapeutics. "Acknowledging success of BHT-3009, the first drug candidate from Bayhill's antigen-specific platform, current investors paid additional funds into Bayhill to advance its second antigen-specific drug candidate, BHT-3021 for Type 1 diabetes type 1 diabetes n. See diabetes mellitus. , into Phase I/II human clinical trials," Dr. Schwartz said. "Additionally, the Bayhill Board of Directors has appointed David Thompson to the Board. David is a 35 year Eli Lilly business development veteran who is providing strategic insights to the Bayhill management team in support of the company's business development activities to partner drug compounds from the company's two platform technologies." (see David Thompson joins Bayhill board news release: http://www.bayhilltx.com/PressRelease_8.html) BHT-3009 research and clinical data was presented last week at the American Academy of Neurology The American Academy of Neurology (AAN) is a professional society for neurologists and neuroscientists. As a medical specialty society it was established in 1949 by A.B. Baker of the University of Minnesota to advance the art and science of neurology, and thereby promote the best in San Diego. One of two presentations was selected as one of the meeting's "scientific program highlights," and was among the top five percent of the research presented at this year's meeting: News advisory: http://www.bayhilltherapeutics.com/news_advisory.pdf; Abstract: http://www.bayhilltherapeutics.com/AAN_2006_abstract_S02_004.pdf. Investors in the company include: A.M. Pappas Life Science Ventures, Boston Life Science Venture Corp (Taiwan), CMEA CMEA Council for Mutual Economic Assistance CMEA Cellular Message Encryption Algorithm CMEA Canadian Music Educators' Association CMEA Council for Mutual Economic Aid CMEA Certified Machinery Equipment Appraiser CMEA Colorado Music Education Association Ventures, De Novo [Latin, Anew.] A second time; afresh. A trial or a hearing that is ordered by an appellate court that has reviewed the record of a hearing in a lower court and sent the matter back to the original court for a new trial, as if it had not been previously heard nor decided. Ventures, Grand Cathay Venture Capital Company LTD LTD 1 Laron-type dwarfism 2 Leukotriene D 3 Long-term depression, see there 4. Long-term disability (Taiwan), Latterell Venture Partners, Lilly Ventures, Montreux Equity Partners, Morgenthaler Ventures, PAC-LINK Bio Management Corp (Taiwan), (Quintiles Quintiles Transnational Corp. is a contract research organization which serves the pharmaceutical, biotechnology and healthcare industries. History Quintiles was founded in 1982 by Dennis Gillings and as of 2007 it has 18,000 employees. ) PharmaBio Development, Prudence Venture Investment Corp (Taiwan), U.S. Venture Partners, Vertical Group. About Bayhill Therapeutics Bayhill Therapeutics Inc. is focused on the translation of research into therapeutics by developing novel drugs for the treatment of autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause . The company has established a product platform of antigen-specific therapeutics, BHT-DNA(TM), with broad potential applications in treating autoimmune diseases, including multiple sclerosis, Type 1 diabetes, and rheumatoid arthritis. In addition, Bayhill is developing a second therapeutic program, BHT-Oligo(TM), using novel oligonucleotide-based drugs for treating autoimmune diseases. For further information, please visit: http://www.bayhilltx.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion